Stay updated with breaking news from Nasdaq Labp. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Landos Biopharma (NASDAQ:LABP – Get Rating) posted its earnings results on Friday. The company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.01, Yahoo Finance reports. Landos Biopharma Stock Performance NASDAQ:LABP opened at $0.30 on Friday. The firm has a market capitalization of $9.28 million, a PE ratio […]
Seasoned Pharmaceutical Executive Brings 25+ Years of Experience With a Focus on Successful Commercialization Company Remains On Track to Complete Review...
Landos Biopharma (NASDAQ:LABP – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Wednesday, Zacks.com reports. The brokerage currently has a $2.00 price objective on the stock. Zacks Investment Research‘s target price would indicate a potential upside of 11.11% from the […]
Landos Biopharma (NASDAQ:LABP – Get Rating) had its price target cut by stock analysts at Raymond James from $24.00 to $9.00 in a research note issued on Friday, Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Raymond James’ price target points to a potential upside of 400.00% from the stock’s previous […]
Continued Progress Towards Optimizing Clinical Development Plans On Track to Initiate Phase 2b Study of Omilancor in Ulcerative Colitis Later this Year ...